Diclegis, a clinically proven combination of pyridoxine and doxylamine succinate, has been approved by regulatory authorities including the FDA and European Medicines Agency for treating moderate-to-severe nausea and vomiting in pregnancy. However, a BBC investigation reveals significant disparities in its availability across English NHS trusts, with some regions providing full coverage while others restrict access or leave pregnant patients to fund treatment privately.
This inconsistent approach creates a postcode lottery affecting maternal healthcare equity. Nausea and vomiting in pregnancy affects 60–80% of pregnant women and can substantially impact quality of life and clinical outcomes. Despite decades of international use and established safety profiles, the medication’s accessibility remains fragmented across the health service, raising concerns about equitable access to evidence-based care.
The variation in regional formulary decisions highlights systemic challenges in standardising maternal healthcare provision across NHS trusts, potentially leaving pregnant women without reliable access to recommended treatments based on geography rather than clinical need.
Read the full article on GMJ Newsroom.
Was this article helpful?
